Update on emerging therapies for multiple sclerosis.
The American Academy of Neurology is an international professional organization of more than 22,000 neurologists and neuroscience professionals. This year the annual meeting was held in Toronto, ON, Canada. A large number of scientific sessions presented numerous advances in the diagnosis, molecular pathogenesis and treatment of Alzheimer's disease and dementia, cerebrovascular and neuromuscular disorders, as well as the rapidly changing areas of genetic testing and stem cell research. This meeting report focuses on the latest therapies in the treatment of multiple sclerosis (MS).
Yiu
Eppie M
EM
The Hospital for Sick Children, Toronto, Canada.
Banwell
Brenda
B
D017338:Cladribine / Q000627:therapeutic use*; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods; D059630:Mesenchymal Stem Cells; D009103:Multiple Sclerosis / Q000503:physiopathology / Q000628:therapy*; D009462:Neurology / Q000379:methods*; D011409:Propylene Glycols / Q000627:therapeutic use*; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D017338:Cladribine; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine